Organogenesis Inc. has entered into a collaborative researchagreement under which Tufts University School of VeterinaryMedicine will conduct preclinical trials of the company's DenseFibrillar Collagen for two orthopedic applications.

Tufts will evaluate the strength, durability and healingcharacteristics of DFC for tendon repair and tendon andligament replacement in humans and animals. Other terms ofthe agreement weren't disclosed.

DFC recruits fibroblasts, which produce and deposit collagenand elastin. DFC will be placed around tendons and ligaments,much like a sleeve. After the tendon or ligament heals, the DFCwill biodegrade.

Shares of the Cambridge, Mass., company (AMEX:ORG) rose$1.13 to $19.25.

(c) 1997 American Health Consultants. All rights reserved.